Literature DB >> 27387649

Parkinsonism Driven by Antipsychotics Originates from Dopaminergic Control of Striatal Cholinergic Interneurons.

Geetika Kharkwal1, Karen Brami-Cherrier1, José E Lizardi-Ortiz2, Alexandra B Nelson3, Maria Ramos1, Daniel Del Barrio1, David Sulzer2, Anatol C Kreitzer4, Emiliana Borrelli5.   

Abstract

Typical antipsychotics can cause disabling side effects. Specifically, antagonism of D2R signaling by the typical antipsychotic haloperidol induces parkinsonism in humans and catalepsy in rodents. Striatal dopamine D2 receptors (D2R) are major regulators of motor activity through their signaling on striatal projection neurons and interneurons. We show that D2R signaling on cholinergic interneurons contributes to an in vitro pause in firing of these otherwise tonically active neurons and to the striatal dopamine/acetylcholine balance. The selective ablation of D2R from cholinergic neurons allows discrimination between the motor-reducing and cataleptic effects of antipsychotics. The cataleptic effect of antipsychotics is triggered by blockade of D2R on cholinergic interneurons and the consequent increase of acetylcholine signaling on striatal projection neurons. These studies illuminate the critical role of D2R-mediated signaling in regulating the activity of striatal cholinergic interneurons and the mechanisms of typical antipsychotic side effects.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27387649      PMCID: PMC4939839          DOI: 10.1016/j.neuron.2016.06.014

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  66 in total

1.  Spontaneous activity of neostriatal cholinergic interneurons in vitro.

Authors:  B D Bennett; C J Wilson
Journal:  J Neurosci       Date:  1999-07-01       Impact factor: 6.167

2.  Regulation of phosphorylation of the GluR1 AMPA receptor in the neostriatum by dopamine and psychostimulants in vivo.

Authors:  G L Snyder; P B Allen; A A Fienberg; C G Valle; R L Huganir; A C Nairn; P Greengard
Journal:  J Neurosci       Date:  2000-06-15       Impact factor: 6.167

Review 3.  Acetylcholine-dopamine balance hypothesis in the striatum: an update.

Authors:  Toshihiko Aosaki; Masami Miura; Takeo Suzuki; Kinya Nishimura; Masao Masuda
Journal:  Geriatr Gerontol Int       Date:  2010-07       Impact factor: 2.730

Review 4.  Muscarinic acetylcholine receptors: novel opportunities for drug development.

Authors:  Andrew C Kruse; Brian K Kobilka; Dinesh Gautam; Patrick M Sexton; Arthur Christopoulos; Jürgen Wess
Journal:  Nat Rev Drug Discov       Date:  2014-06-06       Impact factor: 84.694

5.  Responses of tonically active neurons in the primate's striatum undergo systematic changes during behavioral sensorimotor conditioning.

Authors:  T Aosaki; H Tsubokawa; A Ishida; K Watanabe; A M Graybiel; M Kimura
Journal:  J Neurosci       Date:  1994-06       Impact factor: 6.167

6.  Dopamine modulates release from corticostriatal terminals.

Authors:  Nigel S Bamford; Siobhan Robinson; Richard D Palmiter; John A Joyce; Cynthia Moore; Charles K Meshul
Journal:  J Neurosci       Date:  2004-10-27       Impact factor: 6.167

7.  Muscarinic m4 receptor activation by some atypical antipsychotic drugs.

Authors:  X P Zeng; F Le; E Richelson
Journal:  Eur J Pharmacol       Date:  1997-03-05       Impact factor: 4.432

8.  Changes in extracellular dopamine induced by morphine and cocaine: crucial control by D2 receptors.

Authors:  Francoise Rouge-Pont; Alessandro Usiello; Marianne Benoit-Marand; Francois Gonon; Pier Vincenzo Piazza; Emiliana Borrelli
Journal:  J Neurosci       Date:  2002-04-15       Impact factor: 6.167

9.  Frequency-dependent modulation of dopamine release by nicotine.

Authors:  Hui Zhang; David Sulzer
Journal:  Nat Neurosci       Date:  2004-05-16       Impact factor: 24.884

Review 10.  Dopamine and synaptic plasticity in dorsal striatal circuits controlling action selection.

Authors:  D James Surmeier; Joshua Plotkin; Weixing Shen
Journal:  Curr Opin Neurobiol       Date:  2009-11-05       Impact factor: 6.627

View more
  34 in total

1.  ERK/MAPK Signaling Is Required for Pathway-Specific Striatal Motor Functions.

Authors:  Scott R Hutton; James M Otis; Erin M Kim; Yashna Lamsal; Garret D Stuber; William D Snider
Journal:  J Neurosci       Date:  2017-07-21       Impact factor: 6.167

Review 2.  Disentangling the diverse roles of dopamine D2 receptors in striatal function and behavior.

Authors:  Eduardo F Gallo
Journal:  Neurochem Int       Date:  2019-02-01       Impact factor: 3.921

Review 3.  Dopamine's Effects on Corticostriatal Synapses during Reward-Based Behaviors.

Authors:  Nigel S Bamford; R Mark Wightman; David Sulzer
Journal:  Neuron       Date:  2018-02-07       Impact factor: 17.173

4.  Gnal haploinsufficiency causes genomic instability and increased sensitivity to haloperidol.

Authors:  Mohammad Moshahid Khan; Jianfeng Xiao; T J Hollingsworth; Damini Patel; Dana E Selley; Trevor L Ring; Mark S LeDoux
Journal:  Exp Neurol       Date:  2019-04-26       Impact factor: 5.330

5.  Differential regulation of striatal motor behavior and related cellular responses by dopamine D2L and D2S isoforms.

Authors:  Daniela Radl; Martina Chiacchiaretta; Robert G Lewis; Karen Brami-Cherrier; Ludovico Arcuri; Emiliana Borrelli
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-18       Impact factor: 11.205

6.  Distinctive Modulation of Dopamine Release in the Nucleus Accumbens Shell Mediated by Dopamine and Acetylcholine Receptors.

Authors:  Jung Hoon Shin; Martin F Adrover; Veronica A Alvarez
Journal:  J Neurosci       Date:  2017-10-13       Impact factor: 6.167

7.  Engineered D2R Variants Reveal the Balanced and Biased Contributions of G-Protein and β-Arrestin to Dopamine-Dependent Functions.

Authors:  Samuel J Rose; Thomas F Pack; Sean M Peterson; Kaitlin Payne; Emiliana Borrelli; Marc G Caron
Journal:  Neuropsychopharmacology       Date:  2017-10-25       Impact factor: 7.853

Review 8.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

9.  Altered Baseline and Nicotine-Mediated Behavioral and Cholinergic Profiles in ChAT-Cre Mouse Lines.

Authors:  Edison Chen; Valeria Lallai; Yasmine Sherafat; Nickolas P Grimes; Anna N Pushkin; J P Fowler; Christie D Fowler
Journal:  J Neurosci       Date:  2018-01-25       Impact factor: 6.167

10.  Loss of nigral excitation of cholinergic interneurons contributes to parkinsonian motor impairments.

Authors:  Yuan Cai; Beatriz E Nielsen; Emma E Boxer; Jason Aoto; Christopher P Ford
Journal:  Neuron       Date:  2021-02-17       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.